Liu, H.* ; Forouhar, F.* ; Seibt, T.* ; Saneto, R.* ; Wigby, K.* ; Friedman, J.* ; Xia, X.* ; Shchepinov, M.S.* ; Ramesh, S.K.* ; Conrad, M. ; Stockwell, B.R.*
Characterization of a patient-derived variant of GPX4 for precision therapy.
Nat. Chem. Biol. 18, 91-100 (2022)
Glutathione peroxidase 4 (GPX4), as the only enzyme in mammals capable of reducing esterified phospholipid hydroperoxides within a cellular context, protects cells from ferroptosis. We identified a homozygous point mutation in the GPX4 gene, resulting in an R152H coding mutation, in three patients with Sedaghatian-type spondylometaphyseal dysplasia. Using structure-based analyses and cell models, including patient fibroblasts, of this variant, we found that the missense variant destabilized a critical loop, which disrupted the active site and caused a substantial loss of enzymatic function. We also found that the R152H variant of GPX4 is less susceptible to degradation, revealing the degradation mechanism of the GPX4 protein. Proof-of-concept therapeutic treatments, which overcome the impaired R152H GPX4 activity, including selenium supplementation, selective antioxidants and a deuterated polyunsaturated fatty acid were identified. In addition to revealing a general approach to investigating rare genetic diseases, we demonstrate the biochemical foundations of therapeutic strategies targeting GPX4.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Typ der Hochschulschrift
Herausgeber
Schlagwörter
Cell-death; Selenium Supplementation; Oxidative Damage; Cancer-cells; Glutathione; Expression; Mutant; Dependency; Protects
Keywords plus
Sprache
englisch
Veröffentlichungsjahr
2022
Prepublished im Jahr
2021
HGF-Berichtsjahr
2021
ISSN (print) / ISBN
1552-4450
e-ISSN
1552-4469
ISBN
Bandtitel
Konferenztitel
Konferzenzdatum
Konferenzort
Konferenzband
Quellenangaben
Band: 18,
Heft: 1,
Seiten: 91-100
Artikelnummer: ,
Supplement: ,
Reihe
Verlag
Nature Publishing Group
Verlagsort
Basingstoke
Tag d. mündl. Prüfung
0000-00-00
Betreuer
Gutachter
Prüfer
Topic
Hochschule
Hochschulort
Fakultät
Veröffentlichungsdatum
0000-00-00
Anmeldedatum
0000-00-00
Anmelder/Inhaber
weitere Inhaber
Anmeldeland
Priorität
Begutachtungsstatus
Peer reviewed
POF Topic(s)
30203 - Molecular Targets and Therapies
Forschungsfeld(er)
Genetics and Epidemiology
PSP-Element(e)
G-506900-001
Förderungen
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS)
NINDS NIH HHS
NCI NIH HHS
U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
Copyright
Erfassungsdatum
2022-01-21